Hem/Onc Fellow at @JacobiNCBHosp @EinsteinMed 🩸🧬🔬🫁 | Former Internal Medicine and Chief Resident @SBHBronx | IMG from 🇩🇴 |
Joined November 2010
- Tweets2.8K
- Following635
- Followers252
- Likes2.4K
Jorge O. Sanchez O. retweeted
Thrilled to present at the @NYCHealthSystem Lung Cancer Awareness Symposium today. Great to learn about the phenomenal care NYHH are providing to vulnerable New Yorkers.
Jorge O. Sanchez O. retweeted
📚 Recently wrote this piece for #ASCOConnection on learning during oncology fellowship—and how to keep building those skills beyond training.
A lot of it comes from advice I’ve picked up from mentors and attendings along the way, plus a few lessons from figuring out what has worked (and not worked) for me.
Hope it’s helpful to other fellows navigating the same process!
🔗 connection.asco.org/do/build…
#MedEd #HemeOnc #OncTwitter
Jorge O. Sanchez O. retweeted
Join us & @OncBrothers Dec 11 in New Orleans 8AM-12PM for a complimentary high yield interactive board review session on malignant & classical heme topics right before #ASHapalooza
Followed by a special career panel with our friend @rmistry91 from the @thefellowoncall🩸#ASH26
Jorge O. Sanchez O. retweeted
TKIs in pregnancy for lung cancer: 27 pregnancies, 96.3% live births, 80.8% of mothers responded. They can be considered in selected cases with a multidisciplinary team 🤰🏽🫁 Congrats to Dr. Noseda and Dr. Imbimbo for leading it!
doi.org/10.1007/s40265-026-0…
Jorge O. Sanchez O. retweeted
Thrilled to receive a @LUNGevity research award! Heartfelt thanks to my mentors, Drs. @NarjustFlorezMD and @COlazagasti, their journeys and dedication to the community inspire me to follow their example and give back. Grateful to my program for its support!
Research saves lives.
LUNGevity is proud to invest another $2 million in research to bring the next generation of breakthroughs to people affected by lung cancer.
These awards will support scientists working to detect lung cancer earlier, predict which treatments are most likely to work, overcome drug resistance, and make care more precise, durable, and accessible.
The expert-vetted projects also strengthen the research workforce and advance new strategies for treating RET-positive cancers and EGFR-positive lung cancer.
We are grateful to our donors and partners for supporting these strategic lung cancer research projects that keep the patient at the center of the work.
Learn more about this important research here: lungevity.org/blogs/lungevit…
@adib_elio — @MassGenBrigham
Tatiana Delgado Cruz, MD — @WeillCornell
@FrangiehChris — @ColumbiaMed
@BrendanHeiden — @washumedicine
@SurbhiSinghalMD — @UCD_Cancer
No Joon Song, PhD — @OSUCCC_James
@NehemiasGuevar5 — @SLU_Official
@TejasPatilMD — @CUCancerCenter
@ScientistJerry — @OUCollegeofMed @StephensonCC
@BobakParang — @OSUCCC_James
@LC_Initiative_ @RETpositive @ASTRO_org
Jorge O. Sanchez O. retweeted
NEW in Blood Advances! American Society of Hematology 2026 guidelines for immune thrombocytopenia: initial and second-line therapy for adults with primary ITP ow.ly/Prx55101LvP #clinicalguidelines #ITP #bloodadvances
Jorge O. Sanchez O. retweeted
NPM1 mutations are considered good risk in AML, but variant allele frequency (VAF) matters!
A VAF > 31.44% suggests that the mutation has a wide clonal penetrance, making the AML more chemo-sensitive with greater chance of cure with intensive treatment
However, if VAF < 31.44%, then the mutation is not in the predominant clone, and usually some other mutation or mutations are at play that will mediate future relapse ashpublications.org/blood/ar…
Jorge O. Sanchez O. retweeted
Love my physical copy of some journals (yes I know bad for the environment)…catching up today and came across this gem, easy and relevant for pts and clinicians @RahulBanerjeeMD
Jorge O. Sanchez O. retweeted
Presented at #ESMO26:
In a prespecified interim analysis of a phase 3 trial involving patients with extensive-stage SCLC, the median overall survival was 21.1 months with tarlatamab–durvalumab maintenance therapy and 12.7 months with durvalumab alone. Full DeLLphi-305 trial results: nej.md/4iveIgW
@myESMO
ALT A graph from the Original Article "Tarlatamab–Durvalumab Maintenance for Extensive-Stage Small-Cell Lung Cancer." The trial name, DeLLphi-305, is in parentheses after the title. The graph shows the overall survival (intention-to-treat population). The trial results are being presented at the European Society For Medical Oncology 2026 Congress. The logo of the New England Journal of Medicine is at the bottom.
Jorge O. Sanchez O. retweeted
#ESMO26 DeLLphi-305: tarlatamab+durva vs durva, 1L maintenance ES-SCLC
➡️ OS 21.1 vs 12.7 mo, HR 0.42
➡️ PFS 7.4 vs 1.9 mo, HR 0.34
➡️ CRS 49.6% (G3+ 0.4%)
Amazing to be part of this practice-changing study on the global steering committee!!
@LungCancerRx @OncoAlert @oncodaily
Jorge O. Sanchez O. retweeted
The MSKCC Genitourinary Oncology Service is looking for a motivated, patient-centered, clinical investigator with a focus on urothelial cancer. Join a great team focused on eradicating GU cancers!
msk.wd108.myworkdayjobs.com/…
Jorge O. Sanchez O. retweeted
Haha! It’s a good problem to have so many good therapies 😇. But nowhere close to the complexity of leukemias and AlloSCT.
Here is a brief oversimplified spiel I use for education and I am sure this will get outdated pretty soon as well.
Jorge O. Sanchez O. retweeted
CD markers very simplified!
CD34+ = Blast
CD3+ = T-cell
CD19+ = B-cell
CD33+ = Myeloid
CD34+ = Acute leukemia (but which type?)
CD34+ CD19+ = B-ALL
CD34+ CD3+ = T-ALL
CD34+ CD33+ = AML
CD34- CD33+ = APL (promyelocyte differentiated one step above blast)”
Jorge O. Sanchez O. retweeted
Three things I recommend for using Bispecific antibodies in myeloma:
1) Prophylactic tocilizumab with first dose
2) Monthly IVIG regardless of the IgG level
3) Consider reducing frequency/stopping after excellent response.
This applies to all the approved bispecifics: teclistamab, elranatamab, linvoseltamab, and talquetamab.
Academic centers with expertise and close monitoring capabilities may skip the prophylactic tocilizumab but in general I do not see community adoption without it.
The data on routine IVIG and early use before the IgG levels drop or infections occur is good and sufficient to move forward. It’s recommended in NCCN and mSMART. Bispecifics are better at controlling myeloma than standard triplets and quads, but pose a much higher risk of serious life threatening infections without prophylaxis and careful adjustment of dosing schedule based on response and patient characteristics.
#IMS26
Jorge O. Sanchez O. retweeted
⚠️ التوصيات الحديثة لنقص الحديد وضعت حدود واضحة في متى يسمى نقص حديد بغض النظر عن التغير بالهيموجلوبين 🩸
وهذه نقطة جيدة خصوصًا لبدايات المشكلة وكذلك لحل مشكلة التركيز على الهيموجلوبين فقط دون التركيز على مخزون الحديد
💡 لكن لهذا تفصيل فالرقم ليس واحد للجميع
- الاشخاص في حالات الالتهاب، القولون الالتهابي مثل كرونز والقولون التقرحي، الاورام، الأمراض المعدية والالتهابية
يشخص نقص الحديد ان كان اقل من ١٠٠
- بشكل عام للكبار يشخص نقص الحديد ان كان اقل من ٣٠ وللاطفال تحت ٤ سنوات اقل من ٢٠
- ولكن عند وجود دورة شهرية غزيرة، او حمل مع وجود فقر دم يشخص نقص الحديد ان كان اقل من ٥٠
ولابد الانتباه لنقطة (تشخيص نقص) و (رقم غير كاف لزوال الاعراض)
- فلا تزال توصية الخبراء عند بعض الاعراض مثل تساقط الشعر الكربي، او الشقيقة فان الرقم الموصى به (وشوهد تحسن معه) هو اعلى من ٧٠ (قد لا يسمى نقص حديد، لكن يعتبر غير كاف لزوال الاعراض)
🟢 مثال: امرأة تعاني من تساقط كربي مستمر، مخزون حديد ٥٠، لايوجد مسببات اخرى (يفضل رفعه اكثر من ٧٠ ومراقبة التحسن)
——
كما ان التوصيات تستمر كما هي في الطريقة العلاجية الصحيحة
- يفضل العلاج بالفم (بالحبوب والتغذية)
- العلاج الوريدي لحالات محددة فقط
وبالنهاية، اختر طبيبك بعناية، واستشر قبل اخذ اي علاج
Jorge O. Sanchez O. retweeted
1/4
NEW ASH ITP GUIDELINES: A REAL CHANGE IN FIRST-LINE THERAPY
For adults with primary ITP requiring treatment, ASH now suggests, conditionally:
Steroids + rituximab
or
Steroids + a TPO agent
rather than steroids alone.
Jorge O. Sanchez O. retweeted
PIVOT-CLL - Pirobrutinib, Venetoclax, Obinotuzumab Treatment in First Line CLL [Sep 10, 2026] @NitinJainMD #SOHO2026 #CLLsm #leusm #caxtx Conclusions
